Literature DB >> 2552046

Characterization of insulin-like growth factor I and epidermal growth factor receptors in meningioma.

M Kurihara1, Y Tokunaga, K Tsutsumi, T Kawaguchi, K Shigematsu, M Niwa, K Mori.   

Abstract

Receptors for insulin-like growth factor I (IGF-I) and epidermal growth factor (EGF) were localized and characterized in eight samples of human meningioma (four fibrous, two meningothelial, and two angioblastic types), using quantitative autoradiographic techniques. Effects of both growth factors on deoxyribonucleic acid (DNA) synthesis in the cultured meningioma cells were examined. High numbers of specific binding sites for both IGF-I and EGF were homogeneously present in tissue sections derived from fibrous and meningothelial types of meningiomas, whereas binding sites for these growth factors were not detectable in adjacent leptomeninges. While relatively large numbers of IGF-I binding sites were located in the wall of the intratumoral vasculature, the number of binding sites in the stromal component was lower in angioblastic-type meningiomas, including a low number of EGF binding sites detected only in the stromal portion. Scatchard analysis revealed the presence of a single class of high-affinity binding sites for both IGF-I and EGF in the meningiomas examined (dissociation constant (Kd) = 0.6 to 2.9 nM, and the maximum number of binding sites (Bmax) = 16 to 80 fmol/mg for IGF-I; and Kd = 0.6 to 4.0 nM, Bmax = 3 to 39 fmol/mg for EGF). Both growth factors increased the synthesis of DNA, in a dose-dependent manner, as measured by 3H-thymidine incorporation. The combination of IGF-I and EGF synergistically stimulated the synthesis of DNA, and the effects seen with 10% fetal bovine serum could be reproduced at a concentration of 10(-10) M. These observations can be interpreted to mean that both IGF-I and EGF may be involved in the growth modulation of meningiomas, possibly through paracrine or autocrine mechanisms.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2552046     DOI: 10.3171/jns.1989.71.4.0538

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  16 in total

1.  Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the childhood cancer survivor study.

Authors:  Briana C Patterson; Yan Chen; Charles A Sklar; Joseph Neglia; Yutaka Yasui; Ann Mertens; Gregory T Armstrong; Anna Meadows; Marilyn Stovall; Leslie L Robison; Lillian R Meacham
Journal:  J Clin Endocrinol Metab       Date:  2014-02-25       Impact factor: 5.958

2.  Characterisation of a human glioblastoma cell line (LI) expressing hypothalamic and pituitary hormones.

Authors:  A Savarese; M Annicchiarico-Petruzzelli; G Citro; G Zupi; L G Spagnoli; A Colantoni; P Vernole; A Stephanou; R A Knight; P Guerrieri
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

3.  A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report.

Authors:  Maryam Fouladi; John P Perentesis; Lars M Wagner; Alexander A Vinks; Joel M Reid; Charlotte Ahern; George Thomas; Carol A Mercer; Darcy A Krueger; Peter J Houghton; L Austin Doyle; Helen Chen; Brenda Weigel; Susan M Blaney
Journal:  Clin Cancer Res       Date:  2014-12-02       Impact factor: 12.531

4.  Immunoreactivity and receptor expression of insulinlike growth factor I and insulin in human adrenal tumors. An immunohistochemical study of 94 cases.

Authors:  T Kamio; K Shigematsu; K Kawai; H Tsuchiyama
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

5.  Development of a meningioma in a patient with acromegaly during octreotide treatment: are there any causal relationships?

Authors:  E De Menis; G Tulipano; S Villa; D Billeci; C Bonfanti; P Pollara; P Pauletto; A Giustina
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

6.  Biphasic effects of suramin on 125I-epidermal growth factor binding to human meningiomas.

Authors:  K Tsutsumi; N Kitagawa; M Niwa; S Yamaga; H Khalid; K Taniyama; A Himeno; S Shibata
Journal:  Cell Mol Neurobiol       Date:  1993-12       Impact factor: 5.046

7.  Endothelin receptor in microvessels isolated from human meningiomas: quantification with radioluminography.

Authors:  S Yamaga; K Tsutsumi; M Niwa; N Kitagawa; T Anda; A Himeno; H Khalid; K Taniyama; S Shibata
Journal:  Cell Mol Neurobiol       Date:  1995-06       Impact factor: 5.046

8.  Expression of insulin-like growth factors and their receptors in human meningiomas.

Authors:  T Lichtor; M A Kurpakus; M E Gurney
Journal:  J Neurooncol       Date:  1993-09       Impact factor: 4.130

9.  Hemangiopericytoma in the setting of acromegaly.

Authors:  W Jeffrey Elias; Isa M Hussaina; James B Chadduck; John A Jane; Edward R Laws; M Beatriz S Lopes
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

10.  A selective endothelin ETA antagonist, BQ-123, inhibits 125I-endothelin-1 (125I-ET-1) binding to human meningiomas and antagonizes ET-1-induced proliferation of meningioma cells.

Authors:  N Kitagawa; K Tsutsumi; M Niwa; S Yamaga; T Anda; H Khalid; A Himeno; K Taniyama; S Shibata
Journal:  Cell Mol Neurobiol       Date:  1994-04       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.